Inspire Medical Systems, Inc. Announces Pricing of Initial Public Offering

Download as PDF

MINNEAPOLIS (May 2, 2018) – Inspire Medical Systems, Inc. (“Inspire”), a medical technology
company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea, announced today the pricing of its initial public
offering of 6,750,000 shares of its common stock at a public offering price of $16.00 per share, before
underwriting discounts and commissions. All of the shares of common stock are being offered by Inspire.
In addition, Inspire has granted the underwriters a 30-day option to purchase up to 1,012,500 additional
shares of its common stock at the initial public offering price, less underwriting discounts and
commissions. The shares are expected to begin trading on the New York Stock Exchange on May 3, 2018
under the ticker symbol “INSP.” The offering is expected to close on May 7, 2018, subject to customary
closing conditions.

BofA Merrill Lynch and Goldman Sachs & Co. LLC are acting as joint book-running managers for the
offering. Guggenheim Securities, Stifel and Wells Fargo Securities are acting as co-managers for the
offering.

A registration statement relating to these securities has been filed and was declared effective by the
Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies
of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA
Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department or via email: dg.prospectus_requests@baml.com; or Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via
telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical
Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Inspire Investor and Media Contact
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989